A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed hepatic or pulmonary metastases secondary to adenocarcinoma
of the colon and rectum

- Must have undergone complete resection of hepatic or pulmonary metastases with
curative intent

- No evidence of gross residual disease after surgery

- One or more resected and ablated lesions allowed provided all gross residual
tumor was destroyed by ablation

- Repeated resections of hepatic metastatic disease or resections of extrahepatic
metastases prior to resection of the hepatic metastases allowed provided the
most recent hepatic metastatic resection included total disease resection and/or
ablation

- Must have received at least 2 months of perioperative systemic chemotherapy
(including preoperative and/or postoperative chemotherapy) that was completed at
least 1 month ago

PATIENT CHARACTERISTICS:

Age

- At least 18

Performance status

- Karnofsky 70-100%

Life expectancy

- At least 6 months

Hematopoietic

- Platelet count ≥ 75,000/mm^3

- Hemoglobin ≥ 8.5 g/dL (transfusion or epoetin alfa allowed)

Hepatic

- Bilirubin ≤ 2.0 mg/dL

- Hepatitis B surface antigen negative

- Hepatitis C antibody negative

- No other serious chronic or acute hepatic disease

Renal

- Creatinine ≤ 1.5 mg/dL OR

- Creatinine clearance > 60 mL/min

Cardiovascular

- No New York Heart Association class III or IV cardiac disease

- No other serious chronic or acute cardiac disease

Pulmonary

- No asthma

- No chronic obstructive pulmonary disease

- No other serious chronic or acute pulmonary disease

Immunologic

- No history of autoimmune disease, including, but not limited to, any of the
following:

- Inflammatory bowel disease

- Systemic lupus erythematosus

- Ankylosing spondylitis

- Scleroderma

- Multiple sclerosis

- No HIV infection by ELISA and western blot

- Not immunocompromised (by disease or therapy)

- No allergy to eggs or any component of the study vaccine

- No history of allergy or untoward reaction to prior vaccinia (smallpox) vaccination

- No allergy or untoward reaction to sargramostim (GM-CSF)

- No active acute or chronic infection, including urinary tract infection within the
past 72 hours

- No inflammatory bowel conditions, including, but not limited to, the following:

- Active infectious enteritis

- Eosinophilic enteritis

- No acute, chronic, or exfoliative skin disorders, including any of the following:

- Extensive psoriasis

- Burns

- Impetigo

- Disseminated zoster

- Varicella zoster

- Severe acne

- Other open rashes or wounds

Other

- Not pregnant or nursing

- Fertile patients must use effective contraception

- Able to avoid close contact or household contact for 3 weeks after each vaccination
with the following individuals:

- Children under 5 years of age

- Pregnant or nursing women

- Individuals with prior or concurrent extensive eczema, other eczematoid skin
disorders, or other acute or chronic skin conditions

- Immunosuppressed or immunodeficient individuals

- No medical or psychological condition that would preclude study compliance

- No extensive eczema

- No other serious chronic or acute illness that would preclude study participation

- No other malignancy within the past 5 years except nonmelanoma skin cancer,
controlled superficial bladder cancer, or previously treated carcinoma in situ of the
cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No other concurrent immunotherapy

Chemotherapy

- See Disease Characteristics

- No concurrent chemotherapy

Endocrine therapy

- More than 6 weeks since prior and no concurrent steroid therapy

Radiotherapy

- No concurrent radiotherapy

Surgery

- See Disease Characteristics

Other

- No other concurrent immunosuppressants (e.g., azathioprine or cyclosporine)